HIVdent.org | Drug News

Last Updated: March 28, 2023

*Featured Articles*
	A Treatment Timeline POZ Magazine \| January 17, 2023
	Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV Gilead \| December 22, 2022
	FDA Approves SUNENCA (lenacapavir) for Adults with Limited Treatment Options FDA \| December 22, 2022
	Blue Cross and Blue Shield Accused of Placing Most HIV Drugs into Highest Tiers POZ \| December 8, 2022
	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel JAMA. 2022; doi:10.1001/jama.2022.22246. [epublished online December 1, 2022]
	Exciting alternatives: An overview of long-acting HIV treatment, prevention Healio \| October 2022
	American Academy of HIV Medicine Launches Long-Acting Agent Resource Center American Academy of HIV Medicine \| August 22, 2022
	Long-acting Agent Resource Center website HIV LAA \| August 2022
	2022 HIV Drug Chart POZ \| June 27, 2022
	12 Surprisingly Interesting Facts About Making Medicines And The Pharma Industry Sintered Filter \| May 10, 2022
	Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV HIV.gov \| January 20, 2022
	Updates in the Pipeline of HIV Therapy Infectious Disease Special Edition \| January 14, 2022

*News Updates*
	Interest Grows in Long-Acting Injectables for HIV Treatment Pharmacy Times \| March 17, 2023
	Implementing Long-acting Injectable PrEP with an Eye Toward Equity: Yale's Dr. LaRon ... HIV.gov \| March 2, 2023
	New HIV Treatment and PrEP Guidelines POZ Magazine \| February 13, 2023
	Sunlenca Looks Great for Highly Drug-Resistant HIV. Will It Serve a Broader Purpose? TheBody \| January 31, 2023
	Baseline Resistance to Second-Generation INSTIs, First-Line NRTIs Unlikely in HIV Infectious Disease Advisor \| January 30, 2023
	Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.
	FDA approves Sunlenca for treatment-resistant HIV Medical Xpress \| December 29, 2022
	Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak Am J Ophthalmol Case Rep. 2022 Dec 13;101779. doi: 10.1016/j.ajoc.2022.101779.
	High-Resistance Therapy Options for Treatment-Naïve Patients With HIV ContagionLive \| December 9, 2022
	Antiretroviral Drugs for HIV Clinical Practice Guidelines (IAS,2022) Medscape \| December 9, 2022
	Do Antidepressants Make HIV Meds Less Effective? Plus Magazine \| December 9, 2022
	First clinical trial of possible HIV vaccine shows promising results kpbs.org \| December 8, 2022
	Toolkit: Long-Acting Injectables in HIV Treatment TargetHIV \| November 15, 2022
	Fostemsavir Plus Optimized Background Therapy May Be Viable for MDR HIV
	Dolutegravir Effectively Suppresses HIV in Pregnant Women Contagion Live \| November 2, 2022
	FDA reports shortages of amoxicillin (November 1, 2022) The Hill \| November 1, 2022
	HepB-CpG Vaccination Achieves Maximum Seroprotection in Patients With HIV Infectious Disease Advisor \| October 28, 2022
	Tybost (Cobicistat) - Oral: Uses, Side Effects, Dosages, Interactions Verywell Health \| October 28, 2022
	European Medicines Agency Validates Viiv Healthcare's Marketing Authorisation Application For Cabotegravir Long-Acting Injectable For HIV Prevention ViiV Healthcare \| October 28, 2022
	Gilead's latest Biktarvy data offers hope to HIV patients PMLiVE \| October 25, 2022
	A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection Retrovirology. 2022 Oct 22;19(1):22. doi: 10.1186/s12977-022-00608-1.
	Tolerability Drives Most ART Switch Decisions in Patients Living With HIV/AIDS Contagion Live \| October 21, 2022
	Long-Term Biktarvy Resulted in High Rates of Viral Suppression Infectious Disease Special Edition \| October 20, 2022


*2019 Archives*	*2020 Archives*	*2021 Archives*	*2022 Archives*

Blue Cross and Blue Shield Accused of Placing Most HIV Drugs into Highest Tiers

American Academy of HIV Medicine Launches Long-Acting Agent Resource Center

American Academy of HIV Medicine | August 22, 2022

High-Resistance Therapy Options for Treatment-Naïve Patients With HIV

First clinical trial of possible HIV vaccine shows promising results